Education
About Us
Working with TipRanks
Follow Us
BOUT - ETF AI Analysis
Top Page
Innovator IBD Breakout Opportunities ETF (BOUT)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains over the year and in recent months, indicating positive momentum.
Leading Holdings Showing Strength
Several of the largest positions, including SanDisk and other top names, have delivered strong year-to-date gains that support the fund’s results.
Diversified Sector Mix
Holdings spread across industrials, financials, consumer cyclical, technology, health care, and other sectors help reduce reliance on any single industry.
Negative Factors
High Expense Ratio
The fund’s relatively high fee means more of the investment return is used to cover costs instead of staying with investors.
Heavy U.S. Concentration
With the vast majority of assets in U.S. stocks and only a small slice in Canada, the ETF offers limited geographic diversification.
Exposure to a Weak Top Holding
One of the top positions has shown weak year-to-date performance, which can drag on overall returns if it continues to struggle.
BOUT vs. SPDR S&P 500 ETF (SPY)
AUM13.79M
RegionNorth America
Expense Ratio0.85%
Beta0.99
IssuerInnovator
Inception DateSep 13, 2018
Dividend Yield0.33%
Asset ClassEquity
Index TrackedIBD Breakout Stocks Total Return
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume11,700
30 Day Avg. Volume4,086
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
44.58Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering52
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BOUT Summary
The Innovator IBD Breakout Opportunities ETF (BOUT) is built to track the IBD Breakout Stocks Total Return index, which looks for U.S. companies that appear ready for strong price moves, or “breakouts.” It holds a mix of sectors like industrials, financials, consumer companies, and technology, with well-known names such as Dollar General and Charles Schwab among its top holdings. Someone might invest in BOUT to seek growth by targeting stocks with high upside potential while still getting diversification across many industries. A key risk is that these breakout-focused stocks can be more volatile and may rise or fall faster than the overall market.
How much will it cost me?The Innovator IBD Breakout Opportunities ETF (BOUT) has an expense ratio of 0.85%, which means you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on identifying breakout opportunities in the market rather than passively tracking an index.
What would affect this ETF?The Innovator IBD Breakout Opportunities ETF (BOUT), with its focus on U.S. growth-oriented stocks in sectors like technology and industrials, could benefit from advancements in innovation and increased corporate spending in these areas. However, rising interest rates or economic slowdowns could negatively impact growth-focused companies, especially in sectors like technology and healthcare, which are sensitive to changes in borrowing costs and consumer demand.
BOUT Top 10 Holdings
BOUT is leaning into U.S. growth stories, with a noticeable tilt toward industrials, financials, and consumer names rather than the usual Big Tech headliners. SanDisk has been one of the fund’s engines, rising on solid earnings despite some valuation worries. Financial players like WisdomTree and Charles Schwab are adding steady, if unspectacular, fuel. On the consumer side, Dollar General and Carvana are helping performance, though Carvana’s high expectations make it a bit of a white-knuckle ride. Exzeo, meanwhile, has been lagging and quietly tugging on returns.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Terex | 5.35% | $740.67K | $7.33B | 33.88% | 71 Outperform | |
| SanDisk Corp | 4.99% | $691.34K | $86.26B | ― | 55 Neutral | |
| LivaNova | 3.55% | $491.97K | $3.57B | 34.30% | 63 Neutral | |
| Amentum Holdings, Inc. | 3.48% | $482.35K | $8.88B | 60.71% | 74 Outperform | |
| Legence Corp. Class A | 3.40% | $470.33K | $4.76B | ― | ― | |
| Medline, Inc. Class A | 3.31% | $458.29K | $59.08B | ― | ― | |
| Bilibili | 3.24% | $449.33K | $12.97B | 69.90% | 62 Neutral | |
| Wayfair | 3.23% | $447.94K | $11.85B | 88.16% | 52 Neutral | |
| LB Pharmaceuticals, Inc. | 3.11% | $431.10K | $535.58M | ― | ― | |
| Alphabet Class A | 3.02% | $418.52K | $4.02T | 74.06% | 85 Outperform |
BOUT Technical Analysis
Neutral
―
Price Trends
37.69
Positive
37.95
Positive
37.03
Positive
Market Momentum
0.43
Positive
48.11
Neutral
57.15
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BOUT, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 38.92, equal to the 50-day MA of 37.69, and equal to the 200-day MA of 37.03, indicating a neutral trend. The MACD of 0.43 indicates Positive momentum. The RSI at 48.11 is Neutral, neither overbought nor oversold. The STOCH value of 57.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BOUT.
BOUT Peer Comparison
Comparison Results
Performance Comparison
BOUT
Innovator IBD Breakout Opportunities ETF
38.37
-2.17
-5.35%
BAMD
Brookstone Dividend Stock ETF
―
―
―
TMFE
Motley Fool Capital Efficiency 100 Index ETF
―
―
―
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
STOX
Horizon Core Equity ETF
―
―
―
FFTY
Innovator IBD 50 ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents